Anti–G Protein–Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial

G protein–coupled receptor, class C group 5 member D (GPRC5D) is considered to be a promising surface target for multiple myeloma (MM) immunotherapy. Here, we report the efficacy and safety of anti-GPRC5D chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory (R/R) MM. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Jieyun, Li, Hujun, Yan, Zhiling, Zhou, Dian, Wang, Ying, Qi, Yuekun, Cao, Jiang, Li, Depeng, Cheng, Hai, Sang, Wei, Zhu, Feng, Sun, Haiying, Chen, Wei, Qi, Kunming, Yan, Dongmei, Qiu, Tingting, Qiao, Jianlin, Yao, Ruosi, Liu, Yang, Wang, Xue, Zhang, Yanlei, Peng, Shuixiu, Huang, Chih-Hua, Zheng, Junnian, Li, Zhenyu, Chang, Alex H., Xu, Kailin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414745/
https://www.ncbi.nlm.nih.gov/pubmed/36881785
http://dx.doi.org/10.1200/JCO.22.01824

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10414745/
https://www.ncbi.nlm.nih.gov/pubmed/36881785
http://dx.doi.org/10.1200/JCO.22.01824

Ejemplares similares